Literature DB >> 14514128

Mesangial lupus nephritis in Chinese is associated with a high rate of transformation to higher grade nephritis.

L S Tam1, E K Li, F M Lai, Y K Chan, C C Szeto.   

Abstract

Mesangial lupus nephritis was thought to be a mild form of lupus nephritis. However, case reports suggest that this type of nephritis could be associated with a high rate of transformation to more serious classes. We retrospectively reviewed the clinical features, clinical response at one year following treatment, as well as the long-term outcome of patients with mesangial lupus nephritis identified on their first renal biopsy. The possible clinical parameters that may predict poor outcome were examined. Nineteen patients with a median duration of follow-up of 9.6 (2.5-11.4) years were identified. At one year after biopsy, eight patients achieved complete remission, two patients achieved partial remission and nine patients had no response. Of the 10 responders, four relapsed after a median duration of 53 (42-97) months. Nine out of 10 patients (six nonresponders and four responders who relapsed) who underwent a second biopsy showed transformation to a higher grade nephritis. The long-term outcome remained favourable in nine patients. Responders and patients who were given angiotensin-converting enzyme inhibitors were associated with favourable long-term outcome. Our data highlight that renal biopsy should be repeated early in Chinese patients with mesangial nephritis who failed to respond to treatment in order to identify those who may require intense immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14514128     DOI: 10.1191/0961203303lu446oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  10 in total

1.  Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study.

Authors:  Yuan An; Yunshan Zhou; Liqi Bi; Bo Liu; Hong Wang; Jin Lin; Danyi Xu; Mei Wang; Jing Zhang; Yongfu Wang; Yan An; Ping Zhu; Ronghua Xie; Zhiyi Zhang; Yifang Mei; Xiangyuan Liu; Xiaoli Deng; Zhongqiang Yao; Zhuoli Zhang; Yu Wang; Weiguo Xiao; Hui Shen; Xiuyan Yang; Hanshi Xu; Feng Yu; Guochun Wang; Xin Lu; Yang Li; Yingnan Li; Xiaoxia Zuo; Yisha Li; Yi Liu; Yi Zhao; Jianping Guo; Lingyun Sun; Minghui Zhao; Zhanguo Li
Journal:  Clin Rheumatol       Date:  2018-11-28       Impact factor: 2.980

2.  Characteristics and influence factors of pathologic transformation in the subclasses of class IV lupus nephritis.

Authors:  Jian-jun Gao; Guang-yan Cai; Shu-wen Liu; Li Tang; Xue-guang Zhang; Yang Yang; Pu Chen; Shu-xin Liu; Jia-yao Ji; Suo-zhu Shi; Zhong Yin; Xiang-mei Chen
Journal:  Rheumatol Int       Date:  2011-03-26       Impact factor: 2.631

3.  ISN/RPS 2003 class II mesangial proliferative lupus nephritis: a comparison between cases that progressed to class III or IV and cases that did not.

Authors:  Seung Geun Lee; Yong Mee Cho; Min Wook So; Sung Soo Kim; Yong-Gil Kim; Chang-Keun Lee; Bin Yoo
Journal:  Rheumatol Int       Date:  2011-07-16       Impact factor: 2.631

Review 4.  Diagnosis and treatment of lupus nephritis flares--an update.

Authors:  Ben Sprangers; Marianne Monahan; Gerald B Appel
Journal:  Nat Rev Nephrol       Date:  2012-11-13       Impact factor: 28.314

5.  Long-term renal outcomes of mesangial proliferative lupus nephritis in Chinese patients.

Authors:  Shaofan Wang; Duqun Chen; Ke Zuo; Feng Xu; Weixin Hu
Journal:  Clin Rheumatol       Date:  2021-09-22       Impact factor: 2.980

6.  Long-term Outcome of Lupus Nephritis Class II in Argentine Patients: An Open Retrospective Analysis.

Authors:  Maria Victoria Collado; Enrique Dorado; Silvia Rausch; Graciela Gomez; Marina Khoury; Federico Zazzetti; María Gargiulo; Lorena Suarez; Rafael Chaparro; Sergio Paira; Laura Galvan; Vicente Juarez; Cecilia Pisoni; Mercedes Garcia; Liliana Martinez; Analia Alvarez; Clarisa Alvarez; Juan Barreira; Judith Sarano
Journal:  J Clin Rheumatol       Date:  2016-09       Impact factor: 3.517

7.  Expression of CMIP in podocytes is restricted to specific classes of lupus nephritis.

Authors:  Khedidja Bouachi; Anissa Moktefi; Shao-Yu Zhang; Julie Oniszczuk; Kelhia Sendeyo; Philippe Remy; Vincent Audard; Andre Pawlak; Mario Ollero; Djillali Sahali
Journal:  PLoS One       Date:  2018-11-15       Impact factor: 3.240

8.  Accelerated and Severe Lupus Nephritis Benefits From M1, an Active Metabolite of Ginsenoside, by Regulating NLRP3 Inflammasome and T Cell Functions in Mice.

Authors:  Tsai-Jung Lin; Chung-Yao Wu; Pei-Yi Tsai; Wan-Han Hsu; Kuo-Feng Hua; Ching-Liang Chu; Yu-Chieh Lee; Ann Chen; Sheau-Long Lee; Yi-Jin Lin; Chih-Yu Hsieh; Shin-Ruen Yang; Feng-Cheng Liu; Shuk-Man Ka
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

9.  Citral alleviates an accelerated and severe lupus nephritis model by inhibiting the activation signal of NLRP3 inflammasome and enhancing Nrf2 activation.

Authors:  Shuk-Man Ka; Jung-Chen Lin; Tsai-Jung Lin; Feng-Cheng Liu; Louis Kuoping Chao; Chen-Lung Ho; Li-Tzu Yeh; Huey-Kang Sytwu; Kuo-Feng Hua; Ann Chen
Journal:  Arthritis Res Ther       Date:  2015-11-19       Impact factor: 5.156

10.  Lupus nephritis progression in FcγRIIB-/-yaa mice is associated with early development of glomerular electron dense deposits and loss of renal DNase I in severe disease.

Authors:  Kjersti Daae Horvei; Hege Lynum Pedersen; Silje Fismen; Dhivya Thiyagarajan; Andrea Schneider; Ole Petter Rekvig; Thomas H Winkler; Natalya Seredkina
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.